- Oromucosal Cytokine Therapy: Mechanism(s) of Action
-
Tovey MG
- KMID: 1123161
- Korean J Hepatol.
- 2002 Jun;8(2):125-131.
Oromucosal cytokine therapy allows large amounts of cytokines to be administered with improved outcome and without dose limiting toxicity. Orally administered cytokines exert their effects by a novel two pronged... -
- CITED
-
- Close
- SHARE
-
- Close
- Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus
-
Tamai H, Shingaki N, Mori Y, Moribata K, Kawashima , Maeda Y, Niwa T, Deguchi H, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M
- KMID: 2412052
- Gut Liver.
- 2016 Jul;10(4):617-623.
- doi: 10.5009/gnl15193
BACKGROUND/AIMS: This study aimed to predict sustained viral response (SVR) to low-dose pegylated interferon (PEG-IFN) plus ribavirin of elderly and/or cirrhotic patients with genotype 2 hepatitis C virus (HCV) using... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment of BK virus-associated hemorrhagic cystitis with low-dose intravenous cidofovir in patients undergoing allogeneic hematopoietic cell transplantation
-
Lee SS, Ahn JS, Jung SH, Ahn SY, Kim JY, Jang HC, Kang SJ, Jang MO, Yang DH, Kim YK, Lee JJ, Kim HJ
- KMID: 2160686
- Korean J Intern Med.
- 2015 Mar;30(2):212-218.
- doi: 10.3904/kjim.2015.30.2.212
BACKGROUND/AIMS: BK virus (BKV) has been associated with late-onset hemorrhagic cystitis (HC) in recipients of hematopoietic stem cell transplantation (HSCT). Cidofovir has been used at higher doses (3 to 5... -
- CITED
-
- Close
- SHARE
-
- Close
- Peginterferon Alfa-2a plus Ribavirin for Initial Treatment of Chronic Hepatitis C in Korea
-
Lee H, Choi MS, Paik SW, Kim JH, Kim DY, Lee JH, Koh KC, Yoo BC, Rhee JC, Song SM
- KMID: 760628
- Korean J Hepatol.
- 2006 Mar;12(1):31-40.
BACKGROUND/AIMS: Combination therapy with peginterferon and ribavirin is a standard therapy for western patients with chronic hepatitis C; however, its efficacy remains unclear in East Asian patients. We evaluated... -
- CITED
-
- Close
- SHARE
-
- Close
